Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications

Journal of Clinical Psychiatry

Volumn 59, Issue 6, 1998, Pages 294-299

  Hägg, Staffan ^a   Joelsson, Lars ^b   Mjörndal, Tom ^a   Spigset, Olav ^a   Oja, Greta ^b   Dahlqvist, Rune ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Gallivare Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXAPINE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; FLUPENTIXOL; FLUPHENAZINE; GLIBENCLAMIDE; HALOPERIDOL; IPRATROPIUM BROMIDE; LEVOMEPROMAZINE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LITHIUM; LOXAPINE SUCCINATE; PERPHENAZINE; ZUCLOPENTHIXOL;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; IMPAIRED GLUCOSE TOLERANCE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEIZURE;

EID: 2642639885     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0604     Document Type: Article

References (32)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-795
2. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338
3. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
4. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994;151:1520-1521
5. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994;151:1395
6. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry 1996;153:737-738
7. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996;93:217-218
8. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111
9. Arnesson GA. Phenothiazine derivates and glucose metabolism. J Neuropsychiatry 1964;5:181-198
10. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:978-982
11. Proakis AG, Mennear JH, Miya TS, et al. Phenothiazines-induced hyperglycemia: relation to CNS and adrenal effects. Proc Soc Exp Biol Med 1971;137:1385-1388
12. Dagli AJ. Severe hyperglycaemia following ingestion of chlorpromazine. J Assoc Physicians India 1984;32:762-763
13. Lambert AE, Henquin JC, Orci LO. Chlorpromazine in malignant insulinoma. BMJ 1972;3:701
14. Federspil G, Casara D, Stauffacher W. Chlorpromazine in the treatment of endogenous organic hyperinsulinism. Diabetologia 1974;10:189-191
15. Jori A, Carrara MC. On the mechanism of hyperglycemic effect of chlorpromazine. J Pharm Pharmacol 1966;18:623-624
16. Mennear JH, Miya TS. Chlorpromazine-induced glucose intolerance in the mouse. Proc Soc Exp Biol Med 1970;133:770-773
17. Wannarka GI, Fletcher HP, Maickel RP. Centrally mediated drug-induced hyperglycemia in mice. Neuropharmacology 1993;22:341-346
18. Ammon HPT, Orci L, Steinke J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973;187: 423-429
19. Erle G, Basso M, Federspil G, et al. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 1977;11:15-18
20. Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry 1983;44:347-348
21. Ward JL. Glucose tolerance in schizophrenia. Orthomolecular Psychiatry 1972;44:137-140
22. Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 1969;30:341-344
23. McKee HA, D'Arcy PF, Wilson P. Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 1986;11:297-299
24. Brambilla F, Guastalla A, Guerrini A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976;37:98-103
25. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
26. World Health Organization. Mental Disorders: Glossary and Guide to Their Classification in Accordance With the Ninth Revision of the International Classification of Diseases. Geneva, Switzerland: World Health Organization; 1978
27. WHO Study Group on Diabetes Mellitus. World Health Organisation Technical Reports series 727. Geneva, Switzerland: World Health Organization; 1985
28. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;583:209-216
29. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28: 1039-1057
30. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke: a population perspective. Diabetologia 1995;38:1061-1068
31. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72
32. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-561